Vmbook Online ordering

Spectrum Pharmaceuticals Inc

Sure, here's some general information about SPPI, which trades on the NASDAQ exchange under the ticker symbol "SPPI".

Spectrum Pharmaceuticals, Inc. (SPPI) is a biotechnology company that focuses on developing and commercializing novel drugs to treat cancer and rare diseases. The company's pipeline includes various drugs in different stages of clinical development, including some that are already approved by the FDA.

Here are some key points about SPPI:

* Sympphi Share Price: As of March 12, 2023, the share price of SPPI is $18.70.

* Market Capitalization: SPPI has a market capitalization of around $2.42 billion.

* Earnings: The company's net loss for the third quarter of 2022 was $23.5 million, or $0.29 per basic and diluted share, compared to a net loss of $20.4 million, or $0.33 per basic and diluted share, for the same period in 2021.

* Revenue: SPPI reported total revenue of $32.4 million for the third quarter of 2022, an increase of 26% from $25.8 million for the same period in 2021.

* Products: The company's product portfolio includes Fusilev (leucovorin calcium) and Folotyn (pralatrexate injection). They also have several product candidates in various clinical stages, including ROLONTIS (eflapegrastim), a novel granulocyte-colony stimulating factor.

* Clinical Trials: SPPI has several ongoing clinical trials for its pipeline candidates, including Phase 3 trials for ROLONTIS and POYNARD-2 (pivosertib) for non-alcoholic steatohepatitis (NASH).

Please note that this information may have changed since my knowledge cutoff, and I recommend checking for more up-to-date information. Additionally, this is just a brief overview of the company and should not be considered investment advice. Always do thorough research and consult with a professional financial advisor before making investment decisions.